Eyenuk vs TeraRecon
EyeArt works from color fundus photographs taken on Canon CR-2 AF, Canon CR-2 Plus AF or, per a vendor release in June 2023, Topcon NW400 cameras. A diabetes clinic that already owns one of those cameras gets what Eyenuk describes as a retinopathy grade without an ophthalmologist. openFDA lists two EyeArt decisions, K200667 on August 3, 2020 and K223357 on June 16, 2023.
Retinal photographs and CT or MR studies are different images, so the two products answer separate questions. TeraRecon is advanced visualization first. Its home page lists TeraRecon AV, Intuition, TR Neuro, DETECT and an AI Framework for third-party algorithms, and its own cleared algorithms include Aorta.CT (K243158, January 23, 2025) and Cardiac.Chambers.MR (K241312, November 5, 2024). Hospital radiology departments receive DICOM and HL7 results from the framework in their reporting systems.
Radiology · Reviewed November 2, 2026
Eyenuk
by Eyenuk, Inc.
EyeArt is FDA-cleared autonomous AI that grades diabetic retinopathy from retinal photos, with no physician overread needed.
TeraRecon
by ConcertAI · founded 1997
Advanced CT and MR visualization with cardiac, aorta and neuro AI, plus a vendor-agnostic platform to run third-party AI.
When to pick each one
Eyenuk
- Canon and Topcon fundus cameras
- Retinopathy grade without an ophthalmologist
TeraRecon
- Cardiac MR viewer and post-processing for CT and MR
- AI Framework hosts third-party algorithms beside its own
- DICOM and HL7 results to reporting systems
Score
Each row shows points earned of points available under the published rubric.
Eyenuk
71of 100
TeraRecon
42of 100
| Dimension | Eyenuk | TeraRecon | Difference |
|---|---|---|---|
| FDA clearance | 18 / 18 | 18 / 18 | 0 |
| HIPAA / SOC2 / BAA | 10 / 10 | 0 / 10 | +10 |
| EHR integrations (count) | 0 / 4.2 | 0 / 4.2 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 2.4 | 0 / 2.4 | 0 |
| Peer-reviewed papers | 18.2 / 18.2 | 0 / 18.2 | +18.2 |
| RCT / meta-analysis / systematic review | 7.8 / 7.8 | 0 / 7.8 | +7.8 |
| Funding & adoption signal | 3 / 12 | 8.4 / 12 | -5.4 |
| Pricing transparency | 2.5 / 5 | 2.5 / 5 | 0 |
| Years in market | 0 / 6 | 6 / 6 | -6 |
Scroll horizontally to see every column.
Pricing
Eyenuk
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
TeraRecon
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
Evidence
Eyenuk
FDA decisions
K223357 (opens in new tab)510(k)2023-06-16
EyeArt v2.2.0
K200667 (opens in new tab)510(k)2020-08-03
EyeArt
Peer-reviewed
5 PubMed records name Eyenuk.
- Diagnostic Accuracy of the EyeArt Artificial Intelligence System for Diabetic Retinopathy: A Systematic Review and Meta-Analysis. (opens in new tab)
- A pilot cost-analysis study comparing AI-based EyeArt® and ophthalmologist assessment of diabetic retinopathy in minority women in Oslo, Norway. (opens in new tab)
- [Use of Artificial Intelligence in Diabetic Retinopathy Screening: Experience in a Health Service in Santiago, Chile]. (opens in new tab)
TeraRecon
FDA decisions
K250288 (opens in new tab)510(k)2025-10-23
TeraRecon Cardiovascular.Calcification.CT
K243158 (opens in new tab)510(k)2025-01-23
TeraRecon Aorta.CT (1.1.0)
K241312 (opens in new tab)510(k)2024-11-05
TeraRecon Cardiac.Chambers.MR (1.0.0)
K220349 (opens in new tab)510(k)2022-08-12
TeraRecon Neuro
K200750 (opens in new tab)510(k)2020-11-06
Neuro.AI Algorithm
Show 2 more
K191585 (opens in new tab)510(k)2019-07-12
iNtuition-Structural Heart Module
K180916 (opens in new tab)510(k)2018-09-24
iNtuition-T1 Mapping and T2/T2* Mapping
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | Eyenuk | TeraRecon |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | n/a | 1997 |
| HQ | US | US |
Scroll horizontally to see both columns.
Common questions
Open the full radiology comparison
Acute-care triage, mammography screening, CCTA plaque analysis, mobile MRI. 30+ FDA-cleared platforms across stroke, oncology, cardiac. Enterprise sales only — we compared what's deployed where.